Clinical Report: Effective Management of Newly Developed Plaque Psoriasis with Secukinumab in a Patient Undergoing Peritoneal Dialysis

Overview

This case study reports the treatment of plaque psoriasis in a 61-year-old man undergoing peritoneal dialysis using secukinumab. The patient achieved clearance of psoriatic lesions after 12 months.

Background

Psoriasis is a chronic inflammatory skin disorder that can lead to systemic complications, including chronic kidney disease (CKD) and end-stage renal disease (ESRD). Managing psoriasis in patients on peritoneal dialysis is particularly challenging due to the limitations of conventional therapies and the lack of evidence for biologic agents in this population.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• A 61-year-old man on peritoneal dialysis developed plaque psoriasis six years after initiation of dialysis.
• Initial management included topical corticosteroids and intensified dialysis, but the condition worsened.
• Secukinumab was administered at 300 mg weekly for four weeks, followed by maintenance dosing.
• At 12 months, the patient achieved clearance of psoriatic lesions.
• Further studies are needed to establish guidelines for secukinumab use in this population.

Clinical Implications

This case demonstrates the use of secukinumab in patients with severe psoriasis undergoing peritoneal dialysis.

Conclusion

Further investigation is needed to inform clinical guidelines regarding the treatment of severe plaque psoriasis in patients on peritoneal dialysis.

Related Resources & Content

1. Frontiers in Medicine, 2026 -- Case Report: Successful treatment of new onset plaque psoriasis with secukinumab in a peritoneal dialysis patient
2. Frontiers in Medicine, 2026 -- A systems-oriented Ayurvedic approach in chronic plaque psoriasis with renal inflammatory indicators: a 2-year longitudinal case report
3. Frontiers in Medicine, 2026 -- Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study
4. Frontiers in Immunology, 2026 -- Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice
5. Frontiers in Medicine — Case Report: Dupilumab as a corticosteroid-sparing adjunct in severe mucocutaneous pemphigus vulgaris with prior avascular necrosis and chronic kidney disease
6. EuroGuiDerm/EDF systemic psoriasis guideline (February 2025)
7. Psoriasis | Nature Reviews Disease Primers
8. U.S. Prescribing Information for Secukinumab
9. Frontiers | Case Report: Successful treatment of new onset plaque psoriasis with secukinumab in a peritoneal dialysis patient
10. Successful Treatment with Secukinumab in an Erythrodermic Psoriasis Patient with End-Stage Kidney Disease on Hemodialysis: A Case Report - PubMed
11. Biologic Therapy in Psoriasis Patients with Renal Disease: A Systematic Review - PubMed
12. Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis | Dermatology and Therapy | Springer Nature Link